^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
Excerpt:
...- Lung adenocarcinoma patient with EGFR sensitive mutation as confirmed by needle biopsy;...
Trial ID:
Source:
Title:
A multicenter, open-label, single-arm clinical study of Aumolertinib mesylate as postoperative adjuvant treatment for patients with EGFRm positive stage IB and pure solid stage IA2-3 invasive Non-Small Cell Lung Cancer
Excerpt:
...Patients with primary non-small cell lung cancer with 2 common EGFR mutations（EGFR 19 Del or 21 L858R）; 6. ...
Trial ID:
More C2 evidence
Source:
Title:
A Multicenter, Single-Arm, Phase II Study of High-Dose Almonertinib as First-Line Treatment for Patients with EGFR Exon 21 L858R-Mutated Advanced Lung Adenocarcinoma (LUAD)
Excerpt:
......
Trial ID:
Less C2 evidence
Source:
Title:
98P - Adjuvant aumolertinib in resected EGFR-Mutated Non-Small-Cell Lung Cancer: a multiple-center real-world experience
Published date:
03/23/2023
Excerpt:
A total of 215 patients who underwent radical lung cancer surgery with EGFR-sensitizing mutations from four different medical centers were enrolled and received aumolertinib...2-year DFS was 99%.... Our study further demonstrates the pronounced efficacy of aumolertinib in the postoperative adjuvant treatment of NSCLC with an excellent safety profile.